Patrick Blackburn, MD
Gynecologic Oncology · Mesa, AZNPI 1972999266
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.4%), consulting fees and education — rather than concentrated in one kind of arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 19.7%. 2025 is the largest year on record at $2,215, more than ten times the $152 reported in 2019.
Across 137 payments — averaging $50.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Winter & Ibe GmbH$1K
- Intuitive Surgical$1K
- AstraZeneca$941
- Medical Device Business Services, Inc.$602
- GSK$588
- Eisai Inc.$285
- plus $2K from 31 others
What the payments were for
- Consulting fees$1,37520%
- Travel & lodging$4406%
- Food & beverage$4,07358%
- Education$1,07515%
- Entertainment$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Winter & Ibe GmbH | 2 | $1,375 |
| Intuitive Surgical | 4 | $1,080 |
| AstraZeneca(2 entities) | 21 | $941 |
| Medical Device Business Services, Inc. | 6 | $602 |
| GSK | 14 | $588 |
| Eisai Inc. | 4 | $285 |
| Johnson & Johnson(2 entities) | 9 | $252 |
| Merck | 9 | $205 |
| Incyte Corporation | 7 | $159 |
| Seagen Inc. | 3 | $152 |
| Novartis | 6 | $134 |
| Genentech USA, Inc. | 6 | $130 |
| Daiichi Sankyo Inc. | 4 | $103 |
| Deciphera Pharmaceuticals Inc. | 4 | $99 |
| Genmab U.S., Inc. | 3 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Regeneron Healthcare Solutions, Inc. | 3 | $69 |
| Blueprint Medicines Corporation | 3 | $65 |
| Exelixis Inc. | 2 | $56 |
| Caris MPI, Inc. | 1 | $48 |
| Progenics Pharmaceuticals, Inc. | 2 | $47 |
| Legend Biotech USA Inc. | 2 | $44 |
| ADC Therapeutics America, Inc. | 2 | $43 |
| Rigel Pharmaceuticals, Inc. | 1 | $32 |
| Karyopharm Therapeutics Inc. | 2 | $30 |
| EMD Serono, Inc. | 1 | $28 |
| Clovis Oncology, Inc. | 2 | $27 |
| Lilly USA, LLC | 1 | $27 |
| AbbVie | 1 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Pfizer | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Provepharm Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENDOEYE FLEX DEFLECTABLE VIDEOSCOPE$1,375
- DAVINCI XI$1,000
- LYNPARZA$353
- ZEJULA$240
- LENVIMA$120
- TIVDAK$110
How this compares
$6,980 in reported general payments places this provider in the 60th percentile of 26 gynecologic oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 88 | $984 |
| Megestrol Acetate | 11 | $948 |
| Dexamethasone | 48 | $904 |
| Oxycodone Hcl | 73 | $358 |
| Gabapentin | 23 | $234 |
| Prochlorperazine Maleate | 13 | $189 |
| Olanzapine | 25 | $185 |
| Ondansetron Hcl | 17 | $81 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCOlanzapine | $27 | $18525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 26 gynecologic oncology providers in Arizona.
Other gynecologic oncology in Mesa
- Lyndsay WillmottPhoenix$448K
- Ivor BenjaminPhoenix$371K
- Mike JanicekScottsdale$88K
- Dennis ScribnerScottsdale$76K
- Javier MagrinaScottsdale$49K
- John FarleyPhoenix$43K
- Heather DaltonPhoenix$26K
- Joseph BuscemaTucson$8K
- Arvind BakhruScottsdale$7K
- Shana WingoPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.